Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
Chad Hoskins
Advertisement
Chad Hoskins is the CEO of Phagenesis and brings deep experience leading and building organizations to successfully bring innovative medical technologies to market. Before joining Phagenesis, he served as CEO of Axon Therapies, where he led the development of a novel technology for patients with heart failure.
Articles by Chad Hoskins
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
The Importance of Reframing COVID-19 as a Preventable Event
3
FDA Extends Talzenna-Xtandi to Hormone-Sensitive Prostate Cancer
4
Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai
5